Skip to main content
Benralizumab proves noninferior to mepolizumab for rare vasculitis, EGPA
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Benralizumab proves noninferior to mepolizumab for rare vasculitis, EGPA
User login
Username
Password
Reset your password
Concept
Lead
score
Vasculitis
1
1
Biologic Therapy
0
0.8
Remission
0
0.76
Humanized Monoclonal Antibody
0
0.32
Monoclonal Antibody
0
0.3
COVID-19
0
0.29
Arthralgia
0
0.15
Asthma
0
0.15
Blood
0
0.15
Eosinophils
0
0.15
Epidemiology
0
0.15
Glucocorticoid
0
0.15
Granulomatosis
0
0.15
Headache
0
0.15
Immunosuppressive Therapy
0
0.15
Interleukin
0
0.15
Pandemic
0
0.15
Pennsylvania
0
0.15
Rare Diseases
0
0.15
Receptors
0
0.15
Refractory
0
0.15
Specialty
Lead
score
Rheumatology
1
1
Pharmacist
0
0.9
Edit Tags